This is a snippet of the transcript, sign up to read more.
It is quite compatible because when people invest in a hematology system, they often include CellaVision as part of the purchase, rather than making it a separate capital expense. Integrating it with a partner that has already budgeted for it was the logical approach.
This is a snippet of the transcript, sign up to read more.
Our initial target was the large laboratories, starting with our first large system 15 years ago. It gained traction quickly. However, the large reference laboratories took a bit longer, as they tend to conduct studies and reviews before adopting new technology. Eventually, all major reference laboratories in the US began using it.
This is a snippet of the transcript, sign up to read more.
Since its introduction, the DC-1 has been one of our best products. It allows networks to coordinate their work through the main laboratory, improving quality and speed. Hospitals can purchase the Sysmex integrated system for their main lab and DC-1s for smaller ones. This has been significant since its introduction. Although the first few months were slow due to Covid, demand surged once restrictions eased.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.